natgillin/translations-raw huggingface dataset:
After the last day of treatment with Pirsue, milk from treated cows should not be used for 5 days.
Mleko zdravljenih krav se lahko začne uporabljati po 5 dnevih od zadnjega dneva zdravljenja z zdravilom Pirsue.
Care should, therefore, be taken by the user of the product to avoid contact with the solution.
Z zdravilom Pirsue je zato treba ravnati previdno, da preprečimo stik z raztopino.
Although the two effects actually have the same results, the first is the most important.
Čeprav imata ta dva učinka enake rezultate, je prvi najpomembnejši.
Most of its effects are probably due to this structural similarity.
Večina učinkov je verjetno posledica strukturne podobnosti.
Undesirable effects a.
Neželeni učinki a.
Children (0-17 years):
Otroci (0-17 let):
* frequency not known (cannot be estimated from the available data).
* neznana (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The symptoms of a severe allergic reaction may include:
Simptomi hude alergijske reakcije lahko vključujejo:
- Coagulation factors (Factor IX)
- koagulacijski faktorji (faktor IX)
• If you need long-term treatment, since muscle alterations may appear.
• če potrebujete dolgoročno zdravljenje, saj lahko pride do sprememb mišic.
Please note that these instructions may also apply to medication that you have used before or you can use later.
To navodilo morda velja tudi za zdravila, ki ste jih uporabljali pred tem, ali jih boste uporabljali kasneje.
This test is negative in primary fibrinolysis.
Ta test je pri primarni fibrinolizi negativen.
All these events have also been described as part of the natural evolution of SAH, as a result of diagnostic procedures such as angiography.
Vsi ti dogodki so bili opisani tudi kot del naravnega razvoja SAH kot rezultat diagnostičnih postopkov, kot je angiografija.
If any of these occur while you are taking [Invented name] by mouth, then stop taking [Invented name] and seek immediate medical advice.
• če imate hematurijo (kri v seču) iz zgornjih sečil,
- Hormonal medication such as oestrogens
- hormonska zdravila, kot so estrogeni
Not known*
Neznana*
Do not use a double dose to make up for a forgotten dose but continue to use the vials as usual.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek, temveč z uporabo vial nadaljujte, kot običajno.
Unknown frequency:
Neznana pogostnost:
Elderly patients and patients with renal failure:
Starejši bolniki in bolniki z odpovedjo ledvic:
The safety and efficacy of EACA in children aged 0 to 17 years have not been established.
Varnost in učinkovitost aminokaprojske kisline pri otrocih, starih med 0 in 17 let, nista bili dokazani.
Fertility There are no clinical data on the effects of [invented name] on fertility.
Plodnost Ni podatkov o vplivu [izmišljeno ime] na plodnost.
Take this leaflet with you.
S seboj vzemite to navodilo za uporabo.
Therapeutic subgroup: Antihemorrhagics Pharmacotherapeutic group: Antifibrinolytics ATC code: B02AA01.
Terapevtska podskupina: antihemoragiki Farmakoterapevtska skupina: antifibrinolitiki Oznaka ATC: B02AA01.
Very rare
Redki zelo redki
When skeletal myopathy occurs, the possibility of damage to the cardiac muscle must also be considered.
Pri pojavu skeletne miopatije je treba pomisliti tudi na možnost poškodovane srčne mišice.
Plasmin can act on other clotting system components such as factors V and VIII and, in particular, fibrinogen.
Plazmin lahko deluje na druge sestavine strjevalnega sistema, kot sta faktorja V in VIII, in zlasti na fibrinogen.
Please inform your doctor or pharmacist if you are taking or have recently taken any other medicine, even those obtained without a prescription, homeopathic, herbal and other healthrelated products, as it may be necessary to stop the treatment or adjust the dose of one of them.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli zdravilo, tudi če ste ga dobili brez recepta, homeopatske, zeliščne ali druge zdravilne pripravke, saj bo morda treba zdravljenje prekiniti ali prilagoditi odmerek.
• If you are allergic to aminocaproic acid or to any of the other ingredients of this medicine.
• če ste alergični na aminokaprojsko kislino ali katero koli sestavino tega zdravila,
The following adverse reactions have been reported from clinical trials, post-authorisation safety studies and from spontaneously-reported cases with the following frequencies: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Med kliničnimi preskušanji, študijami varnosti po odobritvi dovoljenja za promet z zdravilom in spontanimi poročili poročajo o naslednjih neželenih učinkih z naslednjimi pogostnostmi: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do < 1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000).
Allergic reactions may occur uncommonly in patients receiving [Invented name] (in fewer than 1 in 100 patients but more than 1 in 1000 patients).
Alergijske reakcije se lahko pri bolnikih, ki uporabljajo zdravilo [Izmišljeno ime] pojavijo občasno (pri manj kot 1 od 100 bolnikov, a več kot 1 od 1.000 bolnikov).
This drug must not be administered without a definitive diagnosis and/or laboratory findings indicating hyperfibrinolysis (hyperplasminaemia).
Zdravila se ne sme uporabiti brez jasne diagnoze in/ali laboratorijskih izvidov, ki kažejo na hiperfibrinolizo (hiperplazminemijo).
Tell your doctor and stop using [invented name] if you experience:
Obvestite svojega zdravnika in prenehajte uporabljati zdravilo [Izmišljeno ime], če se pojavi kateri koli od naslednjih učinkov:
Carcinogenesis, mutagenesis and fertility disorders: No long-term studies have been conducted in animals to evaluate the carcinogenic or mutagenic potential of aminocaproic acid.
Karcinogeneza, mutageneza in motnje plodnosti: Pri živalih niso izvedli dolgoročnih študij, da bi ocenili karcinogeni ali mutageni potencial aminokaprojske kisline.
• dizziness, ringing or buzzing in ears,
• omotica, zvonjenje ali brenčanje v ušesih
• reduction in blood platelets which increases risk of bleeding or bruising
• zmanjšanje števila krvnih ploščic, kar poveča tveganje za krvavitve ali modrice
• increased pressure in the brain that can result in severe headache, visual disturbance,
• povečan tlak v možganih, ki lahko povzroči močne glavobole, motnje vida, bruhanje, omotico,
Total dosage should not exceed 18 g/m2 (600 mg/kg) in 24 hours.
Skupni odmerek ne sme preseči 18 g/m2 (600 mg/kg) v 24 urah.
• difficult or laboured breathing,
• težko ali oteženo dihanje
In case of overdose with <Aminocaproic acid-containing medicinal products>, tell your doctor or pharmacist immediately, go to the nearest hospital.
V primeru prevelikega odmerka zdravila <zdravila, ki vsebujejo aminokaprojsko kislino>, o tem takoj obvestite zdravnika ali farmacevta ali pojdite v najbližjo bolnišnico.
The consequences ranged from absence of effects and transient hypotension to acute renal failure resulting in death.
Posledice segajo od odsotnosti učinkov in prehodne hipotenzije do akutne ledvične odpovedi s posledično smrtjo.
It has been shown that there are evident relationships between the proteolytic activity of plasmin and the system that forms quinines, polypeptides with different biological effects basically related to inflammation and allergy.
Pokazalo se je, da obstajajo jasna razmerja med proteolitično aktivnostjo plazmina in sistemom, ki tvori kinine, polipeptide z različnimi biološkimi učinki, ki so v osnovi povezani z vnetjem in alergijo.
The clinical relevance of these findings is unknown (see section 5.3).
Klinični pomen teh ugotovitev ni znan (glejte poglavje
Aminocaproic acid has an inhibitor effect on this system, which takes place on two levels: on the one hand, at relatively low concentrations, it inhibits the action of plasminogen activators by a competitive mechanism; on the other, at higher concentrations it inhibits plasmin activity.
Aminokaprojska kislina ima zaviralni učinek na ta sistem, ki se odvija na dveh ravneh: po eni strani pri relativno nizkih koncentracijah zavira delovanje aktivatorjev plazminogena s kompetitivnim mehanizmom; po drugi strani pa pri višjih koncentracijah zavira aktivnost plazmina.
Rapid intravenous administration should be avoided, as it can cause hypotension, bradychardia and/or arrhythmias.
Hitro intravensko infundiranje je treba preprečiti, saj lahko povzroči hipotenzijo, bradikardijo in/ali aritmije.
If any of these occur during administration of [Invented name] your doctor/surgeon will stop treatment with the drug.
Če se med uporabo zdravila [Izmišljeno ime] pojavi kar koli od naštetega, bo vaš zdravnik/kirurg prenehal zdravljenje s tem zdravilom.
• skin rash with small, flat, red spots;
• kožni izpuščaj z majhnimi, ploskimi, rdečimi pikami
Some patients have tolerated doses of up to 100 g, while cases of acute kidney failure have been described after a dose of 12 g.
Nekateri bolniki so prenašali odmerke do 100 g, vendar so primere akutne odpovedi ledvic opisali že po odmerku 12 g.
• If bleeding is due to a condition called disseminated intravascular coagulation.
• če je krvavitev posledica bolezni, imenovane diseminirana intravaskularna koagulacija.
It is widely distributed (it easily spreads to the tissues, appearing in semen, synovial fluid and foetal tissue) and it is excreted in urine, largely unaltered, with a terminal elimination half life of approximately 2 hours.
Dobro se porazdeli (v tkivu se preprosto širi, pojavi se v spermi, sinovijski tekočini in tkivu zarodka) in se izloči s sečem, v veliki meri nespremenjena, s končnim razpolovnim časom približno 2 uri.
The most important affect the fibrinolytic enzyme system, the mechanism responsible for dissolving fibrin meshes and, therefore, clots.
Najpomembnejši vplivajo na fibrinolitični encimski sistem, mehanizem, ki je odgovoren za raztapljanje fibrinskih mrežic in s tem strdkov.
Neurological effects
Nevrološki učinki
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se s svojim zdravnikom ali s farmacevtom, preden vzamete katero koli zdravilo.
• swelling of your eyelids, face, lips and tongue
• otekanje vek, obraza, ustnic in jezika
If any of the side effects is serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če kateri koli neželeni učinek postane resen ali če opazite kateri koli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
In case of dizziness or drowsiness, driving vehicles and using machines is not recommended.
V primeru omotice ali dremavosti ni priporočljivo voziti avtomobila ali upravljati s stroji.
Thrombophlebitis, a possibility with all intravenous treatments, should be avoided, paying special attention to appropriate needle insertion and fixation.
Tromboflebitis, do katerega lahko pride pri vseh intravenskih zdravljenjih, je treba preprečiti, ob čemer je treba posebno pozornost nameniti ustrezni vstavitvi in pritrditvi igle.
If you are pregnant, thinking about becoming pregnant or are breastfeeding, ask your doctor or pharmacist before starting this treatment.
Če ste noseči, načrtujete zanositev ali dojite, se posvetujte s svojim zdravnikom ali farmacevtom, preden vzamete to zdravilo.
• decrease in blood pressure;
• zmanjšanje krvnega tlaka
Aminocaproic acid should therefore not be administered in case of haematuria originating in the upper urinary tract unless the expected benefits more than exceed the risks.
Aminokaprojske kisline se zato ne sme uporabiti v primeru hematurije, ki izvira v zgornjih sečilih, razen če so pričakovane koristi večje od tveganj.
Effects on ability to drive and use machines No studies have been conducted on the effects on the ability to drive and use machines.
Vpliv na sposobnost vožnje in upravljanja s stroji Študij o vplivu na sposobnost vožnje in upravljanje s stroji niso izvedli.
Aminocaproic acid is not very toxic, so intoxication can only occur in very exceptional cases, such as in cases of relative overdose with kidney failure.
Aminokaprojska kislina ni zelo toksična, zato se zastrupitev pojavi le v izjemno redkih primerih, kot na primer v primerih relativnega prevelikega odmerjanja z odpovedjo ledvic.
The most commonly reported adverse reactions during treatment are dizziness, hypotension and headache; hypotension is more likely to occur with rapid infusion.
Neželeni učinki, o katerih so med zdravljenjem najpogosteje poročali, so omotica, hipotenzija in glavobol; bolj verjetno je, da se bo hipotenzija pojavila pri hitrem infundiranju zdravila.
Rapid infusion
Hitro infundiranje
Warnings and precautions .
Opozorila in previdnostni ukrepi
The administration of the equivalent to the maximum therapeutic dose in humans in the diet of rats caused fertility disorders in both sexes.
Dajanje odmerka, ki pri ljudeh ustreza največjemu terapevtskemu odmerku, v prehrano podgan, je povzročilo motnje plodnosti pri obeh spolih.
Aminocaproic acid should not be used when there is evidence of an active intravascular clotting process (see section 4.4).
Aminokaprojske kisline se ne sme uporabiti ob znakih aktivnega intravaskularnega strjevanja krvi (glejte poglavje 4.4).
• sudden shortness of breath or difficulty in breathing, sudden coughing for no apparent reason, chest pain and pain on breathing (as these may suggest a blood clot in the lungs),
• nenadna kratka sapa ali težave z dihanjem, nenaden kašelj brez očitnega vzroka, bolečine v prsih in bolečine pri dihanju (to lahko nakazuje na krvni strdek v pljučih),
- Euglobulin clot test: abnormal in primary fibrinolysis and normal in DIC.
- Evglobulinski test strjevanja: nenormalen pri primarni fibrinolizi in normalen pri DIK.
The following tests can be performed to distinguish between the two disorders: - Platelet count: it is usually reduced in DIC but not in primary fibrinolysis.
Za razlikovanje med tema dvema motnjama so na voljo naslednji testi: - Število trombocitov: običajno je pri DIK zmanjšano, ne pa tudi pri primarni fibrinolizi.
The maximum daily dose should not exceed 24 g.
Največji dnevni odmerek ne sme preseči 24 g.
Aminocaproic acid inhibits the effect of plasminogen activators and, to a lesser extent, plasmin activity.
Aminokaprojska kislina zavira učinek aktivatorjev plazminogena in v manjšem obsegu tudi aktivnost plazmina.
• problems with bleeding or clotting,
• težave s krvavitvijo ali strjevanjem
Serious cases of myopathy and rhabdomyolysis have been reported; these are generally reversible of discontinuation of treatment but CPK must be monitored in patients undergoing prolonged treatment and treatment stopped if any elevation in CPK occurs.
Poročali so o resnih primerih miopatije in rabdomiolize; ti so običajno po prekinitvi zdravljenja reverzibilni, vendar je treba pri bolnikih, ki se zdravijo dalj časa, spremljati CPK in zdravljenje pri zvišanju ravni CPK takoj ustaviti.
However, the anti-haemorrhagic effect of aminocaproic acid is not necessarily linked to the presence of fibrinolysis in blood shown by the respective tests.
Vendar pa antihemoragični učinek aminokaprojske kisline ni nujno povezan s prisotnostjo fibrinolize v krvi, kar kažejo zadevni testi.
• Talk to your doctor before you are given X:If you have poor kidney function.
• Pred začetkom uporabe zdravila X se posvetujte s svojim zdravnikom: če imate okvarjeno delovanje ledvic,
• pain or skin death at the injection site
• bolečina ali odmrla koža na mestu injiciranja
No treatment is known for overdose, although there is evidence that aminocaproic acid is eliminated by haemodialysis and can be eliminated by peritoneal dialysis.
Za prevelik odmerek ni znanega zdravljenja, čeprav obstajajo dokazi, da se aminokaprojska kislina izloča s hemodializo in se lahko izloči s peritonealno dializo.
In this case, the medicinal product should be adjusted to the degree of kidney failure, or eventually be discontinued.
V tem primeru je treba zdravilo prilagoditi ravni odpovedi ledvic ali uporabo prekiniti.
• significant bleeding induced by thrombolytic drugs;
• močna krvavitev, ki jo povzročijo trombolitiki;
DATE OF REVISION OF THE TEXT [To be completed nationally
DATUM ZADNJE REVIZIJE BESEDILA [izpolni država članica]
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from aminocaproic acid therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z aminokaprojsko kislino, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Aminocaproic acid is an amino acid that is structurally similar to other physiological amino acids, especially two fundamental amino acids, lysine and arginine.
Aminokaprojska kislina je aminokislina s podobno strukturo kot druge fiziološke aminokisline, zlasti dve esencialni aminokislini, lizin in arginin.
• unusual aches or pains in your muscles that go on for longer than you might expect (as these can result in kidney problems and potentially life-threatening muscle damage [rhabdomyolysis])
• neobičajne bolečine v mišicah, ki trajajo dlje, kot bi pričakovali (povzročijo lahko težave z ledvicami in potencialno življenjsko nevarno poškodbo mišic [rabdomiolizo])
• heavy menstrual periods;
• močna menstrualna krvavitev;
Other side effects are:
Drugi neželeni učinki:
The patient received 2 g of aminocaproic acid every 6 hours to make a total dose of 26 g. The patient died from prolonged cerebrovascular haemorrhage.
Bolnik je vsakih 6 ur prejel 2 g aminokaprojske kisline v skupnem odmerku 26 g. Bolnik je zaradi dalj časa trajajoče cerebrovaskularne krvavitve umrl.
One case of heart and liver damage has been described in humans.
Pri ljudeh je opisan en primer poškodb srca in jeter.
• dark-coloured urine, decreased amount or frequency of urine
• seč temne barve, zmanjšana količina ali zmanjšana pogostnost izločanja seča
However, it should be administered with precaution in cases in which the existence of thrombosis or embolism is suspected, and in renal failure.
Vendar pa jo je treba uporabiti previdno v primerih s sumom na obstoj tromboze ali embolije ter pri ledvični odpovedi.
In oral administration, the contents of the vial can be taken directly or mixed with a little sugar water, broth, milk, etc.
Pri peroralnem načinu uporabe je mogoče vsebino viale vzeti neposredno ali jo primešati manjši količini sladkane vode, juhe, mleka itd.
Angioneurotic oedema
Angionevrotski edem
Symptoms may include severe sore throat with high fever.
Simptomi lahko vključujejo hudo vnetje grla s povišano telesno temperaturo.
If you use more <Aminocaproic acid-containing medicinal products> than you should If you take more <Aminocaproic acid-containing medicinal products> than you should, you may experience a sudden decrease in blood pressure (hypotension), with symptoms including dizziness, fainting, lightheadedness, blurred vision, a rapid, or irregular heartbeat (palpitations), confusion, feeling like you are going to be sick (nausea) or general weakness.
Če uporabite več zdravila <zdravila, ki vsebujejo aminokaprojsko kislino>, kot bi smeli, lahko občutite naglo znižanje krvnega tlaka (hipotenzijo), s simptomi, ki vključujejo omotico, omedlevico, zamegljen vid, hitro ali nepravilno utripanje srca (palpitacije), zmedenost, občutek slabosti (navzeo) ali splošno oslabelost.
Inhibition of plasmin activity
Zaviranje aktivnosti plazmina
However, there is no clear evidence that the administration of aminocaproic acid has been responsible for the few cases described of intravascular clotting after the treatment.
Vendar pa ni jasnih dokazov, da je bilo dajanje aminokaprojske kisline odgovorno za nekaj primerov opisanega intravaskularnega strjevanja po zdravljenju.
If treatment needs to be extended, the maximum dose over 24 hours should not normally exceed 24 g.
Če je treba zdravljenje podaljšati, največji odmerek običajno ne sme preseči 24 g v 24 urah.
The intravenous and oral lethal dose 50 of aminocaproic acid was 3 and 12 g/kg, respectively, in mice and 3.2 and 16.4 g/kg, respectively, in rats.
Intravenski in peroralni smrtni odmerek 50 aminokaprojske kisline je bil pri miših 3 oz. 12 g/kg in pri podganah 3,2 oz. 16,4 g/kg.
The literature contains publications about an increased incidence of certain neurological deficits such as hydrocephaly, cerebral ischaemia or cerebral vasospasm associated to the use of antifibrinolytic agents in the treatment of subarachnoid haemorrhage (SAH).
V literaturi so objave o povečani incidenci nekaterih nevroloških okvar, kot so hidrocefalus, cerebralna ishemija ali cerebralni vazospazem, povezani z uporabo antifibrinolitičnih zdravil pri zdravljenju subarahnoidne krvavitve (subarachnoid haemorrhage, SAH).
Numerous clinical studies show that aminocaproic acid has no thrombogenic effect.
Številne klinične študije kažejo, da aminokaprojska kislina nima trombogenega učinka.
There is no need for dose adjustment in elderly patients.
Pri starejših bolnikih odmerka ni treba prilagajati.
- Aminocaproic acid should not be used in DIC without the concomitant administration of heparin.
- Aminokaprojske kisline se ne sme uporabiti pri DIK brez sočasne uporabe heparina.
The single dose of aminocaproic acid that produces overdose symptoms or considered to be life threatening is unknown.
Primeri, ko bi en odmerek aminokaprojske kisline povzročil simptome prevelikega odmerjanja ali bil ocenjen kot življenjsko nevaren, niso znani.
Administration with Factor IX complex concentrate or anti-inhibitor clotting concentrates Aminocaproic acid should not be administered with Factor IX complex concentrate or anti-inhibitor clotting concentrates, as it could increase the risk of thrombosis.
Dajanje s koncentratom faktorja IX ali koncentrati protizaviralcev strjevanja Aminokaprojske kisline se ne sme uporabiti s koncentratom faktorja IX ali s koncentrati protizaviralcev strjevanja, saj lahko to poveča tveganje za trombozo.
Aminocaproic acid has multiple pharmacological effects.
Aminokaprojska kislina ima več farmakoloških učinkov.
• angioneurotic oedema (rapid swelling of the skin, mucosa and submucosal tissues).
• angionevrotski edem (hitro otekanje kože, sluznice in podsluzničnega tkiva).
• bleeding from the lower urinary tract not caused by surgery (e.g. due to inflammation of the bladder);
• krvavitev iz spodnjih sečil, ki ni posledica operacijea (npr. zaradi vnetja mehurja);
An intravenous dose of 2.3 g/kg was fatal in dogs.
Pri psih je bil intravenski odmerek 2,3 g/kg smrten.
• gastroenterology
• gastroenterološkem
It is unknown whether epsilon aminocaproic acid is excreted in human milk.
Ni znano, ali se epsilon aminokaprojska kislina izloča v materino mleko.
Instead, it appears that said intravascular clotting was probably due to a pre-existing clinical condition, i.e. the presence of DIC.
Nasprotno, kaže, da je intravaskularno strjevanje verjetno posledica obstoječega kliničnega stanja, tj. prisotnosti diseminirane intravaskularne koagulacije (DIK).
• a lumpy skin rash or ‘hives' anywhere on your body
• izbokli kožni izpuščaj ali „koprivnico“ kjer koli na telesu
Like all medicines, aminocaproic acid can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi aminokaprojska kislina neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
[If applicable] <[In oral administration, the content of the ampoule can be drunk as it is or mixed with a little sugared water, broth, milk, etc.]>
[če je smiselno] <[Pri peroralnem načinu uporabe je mogoče vsebino ampule spiti ali jo primešati manjši količini sladkane vode, juhe, mleka itd.]>
- Protamine paracoagulation test: positive in DIC; a precipitate forms when a drop of protamine sulphate is added to “citrate” plasma.
- Test protaminske parakoagulacije: pozitiven pri DIK; ko se kapljica protaminskega sulfata doda plazmi "citrata", nastane usedlina.
As a result of these effects, aminocaproic acid prevents clot destruction by plasmin and thus prevents the appearance of haemorrhages due to excessive fibrinolytic system activity.
Kot rezultat teh učinkov aminokaprojska kislina plazminu prepreči uničevanje strdkov in s tem prepreči nastajanje krvavitev zaradi pretirane aktivnosti fibrinolitičnega sistema.